Cargando…
Beyond LKB1 Mutations in Non-Small Cell Lung Cancer: Defining LKB1less Phenotype to Optimize Patient Selection and Treatment
LKB1 is frequently mutated in non-small cell lung cancer (NSCLC). LKB1-mutated NSCLCs often have a dismal prognosis and receive lower benefit from the currently available therapies. LKB1 acts as a cell emergency brake in low-energy conditions, by modulating the activity of crucial anabolic enzymes....
Autores principales: | Borzi, Cristina, Galli, Giulia, Ganzinelli, Monica, Signorelli, Diego, Vernieri, Claudio, Garassino, Marina Chiara, Sozzi, Gabriella, Moro, Massimo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7697441/ https://www.ncbi.nlm.nih.gov/pubmed/33202760 http://dx.doi.org/10.3390/ph13110385 |
Ejemplares similares
-
LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial
por: Vernieri, Claudio, et al.
Publicado: (2020) -
LKB1 tumor suppressor: Therapeutic opportunities knock when LKB1 is inactivated
por: Zhou, Wei, et al.
Publicado: (2014) -
LKB1 suppression promotes cardiomyocyte regeneration via LKB1-AMPK-YAP axis
por: Qu, Shuang, et al.
Publicado: (2022) -
LKB1 as the ghostwriter of crypt history
por: Jansen, Marnix, et al.
Publicado: (2011) -
AMPK potentiation by LKB1 isoforms
por: Thibert, Chantal, et al.
Publicado: (2015)